Amarin Corp Plc (AMRN)

[Will Lar]

Their first statement in the PR is erroneous (below). I think you contacted them. So they should correct it.

"VASCEPA® (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months. "

Their second statement is nothing but confusing because they used a semicolon (;) instead of a period (.). The two sentences are independent statements and both are correct, but semicolon makes readers feel the second sentence is an elaboration of the first.

"The final results showed a significant reduction in the primary endpoint; icosapent ethyl reduced LAP plaque volume by 17% from baseline to the 18-month scan, whereas there was a progression of LAP plaque volume in the placebo group."